RxDoctor Payments Data

Michael Woolman

Family Medicine · Ogden, UTNPI 1508833450

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,809 of the $8,333 with a category attached, or 81.7%. Eli Lilly accounts for 73.9% of it on its own, with 2 other manufacturers making up the rest. Among family medicine clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,333in general payments, 2019–2025

Across 68 payments — averaging $122.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$6K
  • AstraZeneca$2K
  • Novo Nordisk AS$400
$1,753,295in research payments, 2019–2025

Across 248 payments — averaging $7069.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1.3M
  • AbbVie$258K
  • AstraZeneca$72K
  • Dexcom, Inc.$47K
  • Urovant Sciences Inc$38K
  • Sumitomo Pharma America, Inc.$26K
  • plus $21K from 1 others

What the payments were for

  • Travel & lodging$6,80982%
  • Food & beverage$1,48718%
  • Education$360%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly52$6,160
AstraZeneca15$1,773
Novo Nordisk AS1$400

How this compares

$8,333 in reported general payments places this provider in the 95th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Other family medicine in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →